TargetMol

AG311

Product Code:
 
TAR-T26573
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26573-5mg5mg£930.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26573-50mg50mg£1,821.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26573-100mg100mg£2,319.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
AG311 is an inhibitor of complex I and hypoxia-induced HIF-1α stabilization. In vitro, AG311 induces rapid necrosis in numerous cancer cell lines. Within minutes, exposure to AG311 also results in mitochondrial depolarization, superoxide production, and increased intracellular calcium levels.
CAS:
1126602-42-3
Formula:
C17H15N5S
Molecular Weight:
321.4
Purity:
0.98
SMILES:
Cc1ccc(Sc2cccc3[nH]c4nc(N)nc(N)c4c23)cc1

References

1. Bastian A, Matsuzaki S, Humphries KM, Pharaoh GA, Doshi A, Zaware N, Gangjee A, Ihnat MA. AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1? stabilization. Cancer Lett. 2017 Mar 1;388:149-157. doi: 10.1016/j.canlet.2016.11.040. Epub 2016 Dec 8. PubMed PMID: 27939695; PubMed Central PMCID: PMC5318233. 2. Bastian A, Thorpe JE, Disch BC, Bailey-Downs LC, Gangjee A, Devambatla RK, Henthorn J, Humphries KM, Vadvalkar SS, Ihnat MA. A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer. J Pharmacol Exp Ther. 2015 May;353(2):392-404. doi: 10.1124/jpet.114.220335. Epub 2015 Feb 26. Erratum in: J Pharmacol Exp Ther. 2017 Jan;360(1):225. PubMed PMID: 25720766; PubMed Central PMCID: PMC4407723.